Phreesia (PHR) Reports Q3 Earnings: What Key Metrics Have to Say

For the quarter ended October 2025, Phreesia (PHR) reported revenue of $120.33 million, up 12.7% over the same period last year. EPS came in at $0.10, compared to -$0.25 in the year-ago quarter.The reported revenue represents a surprise of +0.17% over the Zacks Consensus Estimate of $120.13 million. With the consensus EPS estimate being $0, the company has not delivered EPS surprise.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Phreesia performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Average healthcare services Clients: 4,520 versus 4,530 estimated by three analysts on average.Patient payment volume: $1.18 billion versus $1.16 billion estimated by three analysts on average.Payment facilitator volume percentage: 85% versus the two-analyst average estimate of 81.3%.Revenus- Subscription and related services: $55.48 million versus the five-analyst average estimate of $55.44 million. The reported number represents a year-over-year change of +12.4%.Revenus- Network solutions: $37.43 million versus the five-analyst average estimate of $37.46 million. The reported number represents a year-over-year change of +14.4%.Revenus- Payment processing fees: $27.42 million versus $27.25 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +11% change.View all Key Company Metrics for Phreesia here>>>Shares of Phreesia have returned -7.9% over the past month versus the Zacks S&P 500 composite's +1.2% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.Zacks Naming Top 10 Stocks for 2026Want to be tipped off early to our 10 top picks for the entirety of 2026? History suggests their performance could be sensational.From 2012 (when our Director of Research Sheraz Mian assumed responsibility for the portfolio) through November, 2025, the Zacks Top 10 Stocks gained +2,530.8%, more than QUADRUPLING the S&P 500’s +570.3%.Now Sheraz is combing through 4,400 companies to handpick the best 10 tickers to buy and hold in 2026. Don’t miss your chance to get in on these stocks when they’re released on January 5. Be First to New Top 10 Stocks >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Phreesia, Inc. (PHR): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks